Tumor Infiltrating Lymphocytes (TILs) and Tumor Budding in Invasive Breast Carcinoma: Correlation with Known Prognostic Parameters :  TIL and Tumor budding in IBC

Arghya Bandyopadhyay; M Pallavi Krishna

doi:10.32768/abc.2023103241-247

Arghya Bandyopadhyay ⁽¹⁾, M Pallavi Krishna ⁽²⁾

(1) Department of Pathology, NRS Medical College, Kolkata, West Bengal, India, India,

(2) Department of Pathology , Burdwan Medical College, West Bengal, India, India

https://doi.org/10.32768/abc.2023103241-247

Issue
Volume 10, Issue 3, August 2023

Submitted
March 7, 2023

Published
May 20, 2023

Keywords:

Tumour-infiltrating lymphocyte, Tumour Budding, Invasive breast carcinoma.

PDF XML

Abstract

Background: Invasive breast cancer (IBC) has long been thought as non-immunogenic, but in recent decades it has been reported that tumour micro-environment (TME) in breast cancer encompasses tumor-infiltrating lymphocytes (TILs), which help in creating anti-tumor immune response. On the other hand, tumor buddings (TB) from the invasive front of the tumor contribute to invasion and metastasis. We aim to evaluate TILs and TB in IBC and to correlate them with known prognostic parameters.

Methods: In this retrospective study, 50 cases of IBC were included. TILs and TB were observed and graded in H&E Stained slides following standard guidelines. Associations of TILs and TB with known clinicopathological parameters were established by statistical methods.

Results: The majority of cases were invasive breast carcinoma (IBC)-NST (78%). The cases with low TILs (involving <50% of stroma) had a significant correlation with positive lymph node metastasis (P = 0.017) and high-grade TB (P = 0.038). TB was associated with other adverse prognostic parameters such as tumor necrosis (P=0.043) and lympho-vascular invasion (LVI) (P=0.033) and large tumor size.

Conclusion: As tumor budding is associated with known poor prognostic factors such as necrosis, LVI and large tumor size, it can be regarded as a potential biomarker in predicting the aggressiveness of breast cancer. Low TILs are positively associated with invasion and lymph node metastasis of IBC. Thus, assessment of these protumor (TB) and antitumor (TILs) factors could be a promising approach for future research on breast cancer.

Full text article

Generated from XML file

References

Siegel R. Naishadham D. Jemal A. Cancer statistics, 2013. CA Cancer Clin 2013:63:11-30. doi: 10.3322/caac.21590.

Jemal A. Bray F. Center MM, Ferlay J, Ward E. Forman D, et al. Global cancer statistics. CA Cancer J Clin 2011;61:69-90. doi: 10.3322/caac.20107

Burugu S. Asleh-Aburaya K. Nielsen T.O. Immune infiltrates in the breast cancer microenvironment: Detection, characterization and clinical implication. Breast Cancer 2017, 24, 3-15. doi: 10.1007/s12282-016-0698-z

Salgado R, Denkert C, Demaria S, Sirtaine N, Klauschen F, Pruneri G. et al. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: Recommendations by an international TILs working group 2014. Ann Oncol 2015;26:259-71. doi: 10.1093/annonc/mdu450.

Lee HJ, Park IA, Song IH, Shin SJ, Kim JY, Yu JH, et al. Tertiary lymphoid structures: Prognostic significance and relationship with tumour-infiltrating lymphocytes in triple-negative breast cancer. J Clin Pathol 2016;69:422-30. doi: 10.1136/jclinpath-2015-203089.

Denkert C, Loibl S, Noske A, Roller M, Müller BM, Komor M, et al. Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol 2010:28:105-13. doi: 10.1200/JCO.2009.23.7370.

Yu X, Zhang Z. Wang Z. Wu P. Qiu F. Huang J. et al. Prognostic and predictive value of tumor-infiltrating lymphocytes in breast cancer: A systematic review and meta-analysis. Clin Transl Oncol. 2016:18:497-506. doi: 10.1007/s12094-015-1391-y.

Tse BW, Jovanovic L, Nelson CC, de Souza P, Power CA, Russell PJ. From bench to bedside: immunotherapy for prostate cancer. Biomed Res Int. 2014;2014:981434. doi: 10.1155/2014/981434.

Marrone KA, Brahmer JR. Immune checkpoint therapy in non-small cell lung cancer. Cancer J. 2016;22:81-91. doi: 10.1097/PPO.0000000000000178.

Robert C, Schachter J, Long GV, Arance A, Grob J. Mortier L, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med. 2015;372:2521-32. doi: 10.1056/NEJMoa1503093.

El Bairi K, Haynes HR, Blackley E, Fineberg S, Shear J, Turner S et al. The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group. NPJ Breast Cancer. 2021;7(1):150. doi: 10.1038/s41523-021-00346-1.

Valenza C, Taurelli Salimbeni B, Santoro C, Trapani D, Antonarelli G, Curigliano G. Tumor Infiltrating Lymphocytes across Breast Cancer Subtypes: Current Issues for Biomarker Assessment. Cancers. 2023;15(3):767. doi: 10.3390/cancers15030767.

Angelico G, Broggi G, Caltabiano R, Santoro A, Spadola S, D’Alessandris N, et al. Histopathological Evaluation of Tumor-Infiltrating Lymphocytes (TILs) as Predictive Biomarker for Hormone Receptors Status, Proliferative Activity and Clinical Outcome in Her-2 Positive Breast Cancer. Applied Sciences. 2021; 11(15):6788.

Zlobec I, Lugli A. Epithelial mesenchymal transition and tumor budding in aggressive colorectal cancer: Tumor budding as oncotarget. Oncotarget 2010; 1:651-61. doi: 10.18632/oncotarget.199.

Prall F. Tumour budding in colorectal carcinoma. Histopathology 2007:50:151-62. doi: 10.1111/j.1365-2559.2006.02551.x.

Roh MS, Lee JI, Choi PJ. Tumor budding as a useful prognostic 16 marker in esophageal squamous cell carcinoma. Dis Esophagus 2004:17:333-7. doi: 10.1111/j.1442-2050.2004.00436.x.

Kumarguru BN, Anikode SR, Shahanuma S, Aruna K, Venugopal SS, Prashant, BM. Tumor budding in invasive breast cancer – An indispensable budding touchstone. Indian Journal of Pathology and Microbiology 2020;63(5):117-122. doi: 10.4103/IJPM.IJPM_731_18.

Galon J, Angell HK, Bedognetti D, Marincola FM. The continuum of cancer immunosurveillance: prognostic, predictive, and mechanistic signatures. Immunity. 2013 ;39(1):11-26. doi: 10.1016/j.immuni.2013.07.008..

Koelzer VH, Zlobec I, Lugli A. Tumor budding in colorectal cancer--ready for diagnostic practice? Hum Pathol. 2016;47(1):4-19. doi: 10.1016/j.humpath.2015.08.007.

Liang F, Cao W, Wang Y, Li L, Zhang G, Wang Z. The prognostic value of tumor budding in invasive breast cancer. Pathol Res Pract. 2013;209(5):269-75. doi: 10.1016/j.prp.2013.01.009.

Gujam FJ, McMillan DC, Mohammed ZM, Edwards J, Going JJ. The relationship between tumour budding, the tumour microenvironment and survival in patients with invasive ductal breast cancer. Br J Cancer. 2015 ;113(7):1066-74. doi: 10.1038/bjc.2015.287.

Salhia B, Trippel M, Pfaltz K, Cihoric N, Grogg A, Lädrach C, Zlobec I, Tapia C. High tumor budding stratifies breast cancer with metastatic properties. Breast Cancer Res Treat. 2015;150(2):363-71. doi: 10.1007/s10549-015-3333-3.

Lugli A, Karamitopoulou E, Panayiotides I, Karakitsos P, Rallis G, Peros G et al. CD8+ lymphocytes/ tumour-budding index: an independent prognostic factor representing a 'pro-/anti-tumour' approach to tumour host interaction in colorectal cancer. Br J Cancer. 2009 ;101(8):1382-92. doi: 10.1038/sj.bjc.6605318.

DeNardo DG, Barreto JB, Andreu P, Vasquez L, Tawfik D, Kolhatkar N, Coussens LM. CD4(+) T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages. Cancer Cell. 2009;16(2):91-102. doi: 10.1016/j.ccr.2009.06.018.

Authors

Arghya Bandyopadhyay

Department of Pathology, NRS Medical College, Kolkata, West Bengal, India

https://orcid.org/0000-0002-3045-237X

drarghyabanerjee@yahoo.com (Primary Contact)

M Pallavi Krishna

Department of Pathology , Burdwan Medical College, West Bengal, India

https://orcid.org/0000-0001-8763-0168

Author Biography

Arghya Bandyopadhyay, Department of Pathology, NRS Medical College, Kolkata, West Bengal, India

Associate Professor, Department of Pathology

(West Bengal University of Health Sciences)

NRS Medical College, Kolkata, West Bengal, India.

Bandyopadhyay A, Krishna MP. Tumor Infiltrating Lymphocytes (TILs) and Tumor Budding in Invasive Breast Carcinoma: Correlation with Known Prognostic Parameters : TIL and Tumor budding in IBC. Arch Breast Cancer [Internet]. 2023 May 20 [cited 2024 Dec. 21];10(3):241-7. Available from: https://archbreastcancer.com/index.php/abc/article/view/688

Download Citation

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Copyright©. This is an open-access article distributed under the terms of the Creative Commons Attribution-Non-Commercial 4.0 International License, which permits copy and redistribution of the material in any medium or format or adapt, remix, transform, and build upon the material for any purpose, except for commercial purposes.

Most read articles by the same author(s)

Suma Nayek, Sourav Sau, Kaushik Majumdar, Anupam Basu, Arghya Bandyopadhyay, Histomorphology of immunomodulation and PD1 expression in breast cancer tumor draining lymph nodes , Archives of Breast Cancer: Volume 9, Issue 2, May 2022
Nilanjana Mondal, Ambalika Mondal, Ratnaprabha Maji, Anup Kumar Roy, Anis Bandyopadhyay, Gopinath Barui, Arghya Bandyopadhyay, Assessment of Inter-observer Reproducibility of the Residual Cancer Burden Index and Neoadjuvant Chemotherapy Response in Breast Carcinoma , Archives of Breast Cancer: Vol. 11 No. 4 (2024): Volume 11, Number 4,November 2024

INTRODUCTION

Breast cancer (BC) is considered as the most common malignancy in women and is one of the most common causes of cancer related deaths in women. 1 2 BC has long been considered as non immunogenic, but evidencebased research in recent decades consistently indicates that the TME in the BC consists of an extensive population of cells belonging to adaptive and innate immune systems. These cells have been thought to be biologically or clinically pertinent to varying degrees. 3 The TME comprises immune cells which are in direct contact with tumor cells. These are mononuclear TILs cells and are known as intratumoral lymphocytes (iTILs) and the mononuclear cells present in the stromal background are known as stromal lymphocytes (sTILs) and both of these cell types are said to have prognostic significance. 47 Immune targeted therapies for highly immunogenic tumors such as melanoma, prostate cancer, nonsmall cell lung cancers have emerged which are very effective. 810 Evaluation of TILs on H&E stained sections in HER positive and TNBC show good prognostic and predictive values. Based on these findings, many recent studies have reported that TILs can serve as a potential biomarker for antitumor immune response in BC. 1113 The first step of invasion and metastasis in any solid tumor is tumor budding (TB). 4 TB is defined as the presence of single cells or small groups of cells not more than 5 in number at the invasive margin of the tumor. It has been considered as a poor prognostic marker in oesophageal, colorectal carcinomas. 1516 However, evidence of TB and its role as a prognostic marker in breast cancer is limited.

This study was designed to evaluate sTILs and TB in breast cancer. This study was done to find the statistical significance of various clinicopathological factors (age, size of tumor, histological grade, LN status, LVI and necrosis, focality) based on sTILs and TB. The study also focused on detecting the relation between antitumour and protumor factors (TILs and TB respectively) in invasive breast cancer.

METHODS

This retrospective observational study on BC was conducted in the Department of Pathology, Burdwan Medical College and Hospital, over a period of 1.5 years, after being approved the Institutional Ethics Committee. The patients who had received chemotherapy were also excluded. The histopathology slides (H&E stained) which were diagnosed as invasive breast carcinoma (IBC) were collected and their histopathological features were reviewed by an experienced pathologist. In total, 50 cases were analysed for this study. Thorough clinical histories, gross and histopathological findings of mastectomy specimens were retrieved. Immunohistochemical findings were not included in this study.

Evaluation of sTILs

To evaluate sTILs, the percentage of stromal TILs was calculated according to the proposed guidelines set by international TILs working group 2014 (ITILWG). 5 1. Stromal TILs (sTILs) were assessed using light microscope under low power (x10 objective) and were examined and confirmed under high power (x40 objective) on a single field. 2. All the mononuclear cells (lymphocytes and plasma cells) within the borders of invasive tumor were scored. 3. Intratumoral TILs (iTILs) were excluded in this study. 4. TILs which were present outside the tumor border and which were surrounding DCIS and normal lobules were excluded. Even TILs surrounding the crush artefact and necrosis were excluded. 5. sTILs were assessed as a continuous parameter as per recommendations and even dissociated growth patterns of lymphocytes were taken into account. 6. The cases were categorised into 3 groups according to the percentage of sTILs obtained, <10% sTILs, 10 50%,>50% LPBC.

Evaluation of tumor budding 6 1. Firstly, the invasive front of the tumor was identified under scanner power (x4 objective) of light microscope. 2. Tumor buds (≤5 cells) were assessed in low power (x10 objective). 3. Tumor buds were confirmed using high power (x40 objective) of light microscope and details of tumor buds were examined. It was made sure that the mimickers of tumor buds such as macrophages, multinucleate giant cells, artefacts, fibroblasts, endothelial cells, and smooth muscle cells were excluded from scoring. 4. The cytoplasmic and nuclear features of tumor cells proper were compared with tumor buds at the invasive front and the ones which exhibited similar morphology to that of tumor cells proper were counted (except polarity, because it can vary in tumor buds). 5. Tumor buds were counted in 10 high power fields and classified into high tumor budding (>20/10hpf) and low tumor budding (≤20/10hpf) as per the study done by BN Kumarguru et al. 6 Data about sTILs, tumor budding was tabulated in Microsoft excel and analysed using SPSS V.24 software. The Chi square test was used for comparisons between the groups and clinicopathological correlations between the variables. The P value < 0.05 was considered to be statistically significant.

RESULTS

A total of 50 cases diagnosed as invasive carcinoma of breast were included in this study. Of these 50 cases, 46 were IBCNST (92%), and 4 cases were invasive lobular carcinoma (ILC) (8%) ( Table 1).

The lesions were seen in females in the age range of 20 to 70 years. Most cases were seen in the age range between 41 and 50 years (30%) ( Table 1). Twenty five cases in our study had a tumor size ≤5 cm (50%) and the remaining 25 had a tumor size ≥5cm (50%). Lymph node metastasis was observed in the majority of cases (56%). Most of the cases had grades 2 and 3 (40% and 58%, respectively). Necrosis was found in 64% of the cases. The cases positive for LVI were 44% and negative cases were 56%. Perineural invasion (PNI) was found positive in 50% of the cases (Table 2). The sTILs<10% were found in 19 cases (38%), 10 50% sTILs were found in 21 cases (42%) and >50% of sTILs were found in 10 cases (20%). When these sTILs were correlated with clinicopathological variables, it was found that the majority of cases with a tumor size of >5cm had 10 50% of sTILs (28%) and the majority of cases with a tumor size of ≤5cm had <10% of sTILs (28%) as shown in Table 3. This correlation of the percentage of sTILs with tumor size was significant (with P value of 0.030). The correlation of other variables with sTILs showed no statistical significance in our study but 22% of the cases with positive lymph node metastasis showed the presence of 1050% of sTILs and 28% of the cases with a high tumor grade had a low percentage of sTILs (<10%) and 26% of the cases who were positive for necrosis had a low percentage of sTILs (<10%) as shown in Table 3. When sTILs were classified into 2 groups, one group with <50% of sTILs infiltration and the other with >50% sTILs infiltration, it was found that the cases with positive lymph node metastasis had <50% sTILs (P value = 0.017) ( Table 4). The majority of tumors with a small size (<5cm) also showed the presence of <50% sTILs (P value = 0.042). The correlation with other variables showed no statistical significance even in these 2 groups (Table 4). Among the 50 cases, high TB was seen in 37 cases (74%) and low TB was found in 13 cases (26%). The majority of cases with high grade TB were observed in IBCNST (70%). (Table 5) (Figure 1) In this study, when the correlation between TB and clinicopathological variables was examined, it was found that the cases which were positive for necrosis and LVI had a highgrade TB (Pvalue=0.043, P value=0.033, respectively) which was statistically significant. Other variables like the size of tumor, PNI, status of lymph node metastasis, histological type, and the grade of the tumor had no significant correlation with the grade of TB. But the majority of cases with 2 and 3 grades showed high grade tumor buds (32%, 40%, respectively) and 38% of the cases with a large tumor size had a highgrade TB ( Table 5).

The correlation between sTILs and TB was also determined in our study. To do so, sTILs were divided into 2 groups, group 1 (<50% sTILs), and group 2 (>50% sTILs) and these two groups were compared with the lowgrade and highgrade TB. The Chisquare test showed that the cases with <50% of sTILs had a highgrade TB (60%) with the P value of 0.038, which was statistically significant (Table 6), whereas cases with >50% of sTILs did not show any significant correlation with the lowgrade TB in our study.

DISCUSSION

The aim of this study was to evaluate sTILs and TB in invasive breast carcinoma. Previous studies have demonstrated that there is a significant association between the clinical response in patients with a variety of solid tumors and the presence of immune cells. 7 Numerous studies point out that the adaptive immunity mediated by B and T lymphocytes can lead to the formation of sustained and effective antitumor immune response. 5 8 On the other hand, tumor budding is considered as a strong adverse prognostic factor and its prognostic significance has been demonstrated in colorectal cancer. 9 10 TB is considered as the first step in invasion and metastasis. 14 It is associated with poor prognostic factors such as necrosis, lymph node metastasis, high tumor grade and LVI. 11 12 It can be considered as a protumor factor, as it leads to the progression of tumor.

In our study, we attempted to find if there is any significant correlation between sTILs (antitumor factor) and TB (protumor factor) in breast carcinoma. We found that the cases with <50% sTILs infiltration had highgrade TB (P value=0.038) but the cases with >50% sTILs infiltration did not show the presence the lowgrade TB. Lugli et al. 13 did a study on CD8+ lymphocytes /tumor budding index in colorectal cancer and concluded that this index can be used as an independent prognostic factor in colorectal cancer. In their study, they confirmed that in patients with high tumor budding and low CD8+ lymphocytes index, this was associated with tumor progression and worse survival in colorectal cancer patients.

A study by Angelico et al. 8 showed that all patients with an advanced stage of the disease at the time of diagnosis showed low levels of TILs (<10%). Similarly, in our study we found that patients with grade 3 BC had low levels of TILs (<10%), indicating that the aggressive behaviour of BC is inversely proportional to the immune response. We cannot conclude in our study whether immune exhaustion led to aggressiveness in BC or vice versa.

According to DeNardo et al. 14 , T lymphocytes play a role in regulating other immune cells such as macrophages (M1, M2), and they are important for cellular crosstalk in shaping the TME. We could infer from our study that TILs are required for modulating the TME so as to either inhibit or escalate tumor progression. To support this, we have found in our study that the cases in whom the lymph node metastasis was positive, there was <50% infiltration of sTILs (Pvalue=0.017), indicating that a decreased percentage of TILs can lead to metastasis of tumor cells in breast cancer.

When the grade of TB was correlated with clinicpathological variables, it was found that high grade TB was seen in cases, which were positive for necrosis and LVI with significant P values. The majority of cases with high grade TB presented with large tumor size (38%), but no significant correlation between TB and lymph node metastasis, size of the tumor, PNI, grade of tumor was found in our study.

In contrast, studies by Lian F et al. 10 , Gujam et al. 11 and Kumarguru et al. 6 reported a significant association between high TB and LN metastasis, high tumour grade, size of tumour, and tumour stage. The significant association of high TB with necrosis and LVI was also found in a study by Kumarguru et al. 6 , which was not found in our study.

The method of assessing TB is different in various studies. The present study and the study done by Salhia et al. 12 used x40 (high power) objective to count the buds. Contrary to our study, studies done by Liang et al. 10 and Gujam et al. 11 used x20 objective. By using x20 objective, it would be difficult to differentiate tumor buds from other mimickers on H&E stained sections. Hence, using x40 objective is suggested for evaluating tumor buds on H&E stained sections.

CONCLUSION

In this study, it was shown that high grade TB was significantly associated with poor prognostic factors such as necrosis and LVI; hence, it can be considered as a poor prognostic factor because it has the potential to predict the aggressiveness of breast carcinoma. When the association between sTILs (antitumor factor) and TB (protumor factor) was studied, it was found that the cases with<50% infiltration of sTILs had highgrade TB and lymph node metastasis, indicating that reduced local immune response can significantly lead to tumor progression. On the contrary, the presence of high stromal lymphocytic infiltration did not show the suppression of tumor progression and lymph node metastasis in breast carcinoma in our study, indicating that there might be other factors responsible for tumor progression or suppression than TILs.

The present study shows that TILs can be considered as an antitumor factor and TB as a protumor factor. We recommend that further studies should be done to gain a more indepth insight into this antitumor and protumor dynamics in invasive breast cancer along with their prognostic significance as these can be considered to be potential prognostic biomarkers.

CONFLICT OF INTEREST

None to declare.

FUNDING

No funding from public, pharmaceutical companies or any other sources are used in this study.

Histopathology picture of invasive breast carcinoma: showing many tumour buds (white arrows) and high tumour infiltrating lymphocytes. (H & E Stain, 40x)

Read Counter : 675 Download : 5

Share Now

Tumor Infiltrating Lymphocytes (TILs) and Tumor Budding in Invasive Breast Carcinoma: Correlation with Known Prognostic Parameters TIL and Tumor budding in IBC

Abstract

Full text article

References

Authors

Arghya Bandyopadhyay, Department of Pathology, NRS Medical College, Kolkata, West Bengal, India

Most read articles by the same author(s)

Important Links

Contact Info

Article Sidebar

Abstract

Full text article

References

Authors

Arghya Bandyopadhyay, Department of Pathology, NRS Medical College, Kolkata, West Bengal, India

Article Details

Most read articles by the same author(s)

Important Links

Contact Info